BioSpace News Archive

Excision BioTherapeutics, Inc., the developer of CRISPR-based therapies intended to cure viral infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for EBT-101, a CRISPR-based therapeutic candidate in development as a potential functional cure for chronic HIV.

Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer and co-founder of Neumentum, and Dr. Joseph Pergolizzi, Executive Chairman and co-founder of Neumentum, will provide a brief corporate update at the UBS Virtual Biotechnology Private Company Symposium.

Lexicon Pharmaceuticals, Inc. will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 21, 2021 at 10:45 a.m. ET.

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the appointment of patient advocate, political leader, and former state senator Art Torres to its Board of Directors.

GenesisCare—one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom—is collaborating with Lee Health—one of the largest not-for-profit public health systems in Florida—to transform pancreatic patient survival rates

Cerus Corporation (Nasdaq: CERS) today announced that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in the 2021 Cantor Global Virtual Healthcare Conference on Wednesday, September 29, 2021 at 11:20 a.m. ET.

Following Amylyx’s announcement that it intends to submit a New Drug Application (NDA) for AMX0035, The ALS Association today urges the Food and Drug Administration to approve the treatment for all people with ALS as soon as possible.

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that the group has received clearance from the US FDA regarding the IND application to initiate clinical trials of SACT-1, an orally administered repurposed small molecule drug for the treatment of neuroblastoma.

Regulatory News: Aptorum Group Limited today provided a business update and announced financial results for the six months ended June 30, 2021.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Benzinga Healthcare Small Cap Conference.